Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656329 · ClinicalTrials.gov registry record · Phase 3
International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device
A Phase 3 study, sponsored by GE Healthcare.
- Terminated
- Registry status
- Phase 3
- Development phase
- 395
- Enrollment target
NCT02656329 is a Phase 3 study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 395 participants.
The verdict
NCT02656329, a Phase 3 study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 395 participants
- Enrollment target
Study Summary
This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure participants with 25%\<=left ventricular ejection fraction (LVEF)\<=35%, and in particular, for identifying participants who are at low risk for sudden cardiac death and who would not benefit, or may suffer harm, from implantation of an ICD device.
Interventions
- DEVICE Implantable Cardioverter Defibrillator
- DRUG Iobenguane I -123 Injection
- DRUG Thyroid blocking
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2015-12-30 |
| Est. Completion | 2018-05-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02656329
The ClinicalTrials.gov registry entry for NCT02656329 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 395 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Implantable Cardioverter Defibrillator is the first listed.
NCT02656329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02656329 about?
NCT02656329 is a clinical study titled "International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device". This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure parti...
What is the current status of trial NCT02656329?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 395 participants. The study started on 2015-12-30. Estimated completion is 2018-05-04.
What interventions are being tested in trial NCT02656329?
The interventions under investigation include: Implantable Cardioverter Defibrillator (DEVICE), Iobenguane I -123 Injection (DRUG), Thyroid blocking (DRUG).
Who is sponsoring clinical trial NCT02656329?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.